Merck signs up to $3.3 bln cancer drug deal with China-based LaNova
Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...
STAT4h
Pharmalittle: We’re reading about a Merck deal, GSK cancer drug data, and more
In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...
FiercePharma4h
Merck joins American Lung Association in raising awareness of pulmonary arterial hypertension
As the rollout of its recently launched pulmonary arterial hypertension (PAH) drug Winrevair ramps up, Merck is continuing ...
Yale Daily News17h
Yale spin-off company Modifi Bio acquired by Merck in multimillion dollar deal
Bindra and Herzon will also remain as consultants for Merck. According to Bindra, the Modifi Bio team met with Merck in ...
BioPharma Dive3h
Merck, facing threat to Keytruda, buys into new kind of cancer immunotherapy
The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...
Reuters14h
Merck KGaA Q3 earnings rise faster than expected on lower costs
Merck, which previously predicted 2024 sales between 20.7 billion ... is the world’s largest multimedia news provider, ...
The Pharma Letter3h
Merck KGaA shares slip on cautious outlook
Merck, which previously predicted 2024 sales of between 20. ... useful and valuable Life Sciences service that brings ...
The Pharma Letter2h
Merck & Co wades into PD-1/VEGF space via deal with LaNova Medicines
Merck & Co has entered into an exclusive global license to develop, manufacture and commercialize LM-299 from China-based ...
pharmaphorum2d
Merck drug for rare tumour hits phase 3 target
Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...
FierceBiotech2d
Merck KGaA's phase 3 rare tumor trial hits goal, teeing up rivalry with Daiichi and Ono
Merck published phase 3 data on Tuesday. Investigators in China, Europe and North America randomized 94 people with TGCT to ...
FiercePharma1d
AstraZeneca and Merck's Koselugo delivers phase 3 trial win in adults with NF1, teeing up filings
NF1 affects around 1.7 million people worldwide, with about 70% being adults ... before AZ and its partner Merck were able to ...
Joplin Globe8h
Merck to Participate in the Jefferies London Healthcare Conference
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Joseph Romanelli, president, Human Health International, and Dr. Marjorie Green, senior vice president and ...